ROCHE DIAGNOSTICS LIMITED
Location
Founded
1956-09-14
Website
Risk Signals
24759 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Business Services, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about ROCHE DIAGNOSTICS LIMITED
Live alerts from global media, monitored by Business Radar
2025-06-16 (deraktionaer.de)
Sarepta share crashes again: further death - the shareholder
Sarepta share falls by 40%after a second death due to gene therapy of Elevidy.
Read more
2025-02-22 (biospace.com)
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights -
Net cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2 million
Read more
2025-01-28 (fuw.ch)
Roche is said to experience a significantly better year Financial and economy
In the past financial year, the loss of the coronage business and the strong francs slowed down. But now the growth should attract.
Read more
2024-12-12 (zofingertagblatt.ch)
After the fat-loss injections come the weight-loss pills: what they promise – and what Roche has to do with it
Pharmaceutical industry: According to Vips, that many drugs do not come onto the market
Read more
2024-11-14 (manager-magazin.de)
Roche starts late with diet injections: “We don’t decide on the game board”
The pharmaceutical company delayed its early entry into the billion-dollar diet injection business. Now Thomas Schinecker wants to get into the lucrative market - and better balance the financial risks of research.
Read more
2024-10-17 (consalud.es)
Roche in free fall: The company's shares fell 5.88% in the month of September
In September, Roche faced several setbacks that caused a drop in its share value, closing at 287.81 euros, due to uncertainty related to its workforce and the development of clinical trials.
Read more
2024-10-17 (consalud.es)
Roche in free fall: The company's shares fell 5.88% in the month of September
In September, Roche faced several setbacks that caused a drop in its share value, closing at 287.81 euros, due to uncertainty related to its workforce and the development of clinical trials.
Read more
2024-10-13 (bote.ch)
After the fat-loss injections come the weight-loss pills: what they promise – and what Roche has to do with it
Fewer side effects, no yo-yo effect, pill instead of injection: the race for the next breakthrough in the obesity business has already begun.
Read more
2024-09-23 (independent.ie)
Four in 10 workers set for pension auto-enrolment don’t know about scheme
Huge numbers of adults who do not have a pension say they have never heard of the mandatory scheme they are due to be enrolled in.
Read more
2024-09-20 (themarket.ch)
Thomas Bruhin: “The environment speaks for insurance stocks”
Thomas Bruhin, portfolio manager at Zürcher Kantonalbank, sees the stock market facing a balancing act between fantasies of interest rate cuts and economic developments.
Read more
2024-09-20 (themarket.ch)
Thomas Bruhin: “The environment speaks for insurance stocks”
Thomas Bruhin, portfolio manager at Zürcher Kantonalbank, sees the stock market facing a balancing act between fantasies of interest rate cuts and economic developments.
Read more
2024-09-20 (themarket.ch)
Thomas Bruhin: “The environment speaks for insurance stocks”
Thomas Bruhin, portfolio manager at Zürcher Kantonalbank, sees the stock market facing a balancing act between fantasies of interest rate cuts and economic developments.
Read more